Finch Therapeutics Group, Inc., a Somerville, MA-based clinical-stage microbiome therapeutics company, completed a $53m Series C financing.
Backers included OCV Partners, Susquehanna International Group (SIG), Symbiosis LLC and the Trans-Pacific Technology Fund, as well as existing investors Avenir Growth Capital, Morgan Noble, Shumway Capital, and Willett Advisors.
Led by Mark Smith, CEO, Finch Therapeutics is developing novel microbial therapies from microbes that have demonstrated clinically significant impacts on patient outcomes.
The company intends to use the funds to advance its pipeline of novel microbial therapies, including CP101, a Full-Spectrum Microbiota® (FSM®) therapy delivered in an oral capsule that is designed to contain a diverse community of microbiota and restore a balanced microbiome.
The proceeds will also enable Finch to accelerate the development of its FSM therapy for Autism Spectrum Disorder (ASD).
The company has also received FDA Fast Track designation for its pediatric ASD program.
Beyond CDI and ASD, Finch is continuing to expand its pipeline of microbiome-based therapeutics, including a pre-clinical Rationally-Selected Microbiota® (RSM™) program in Inflammatory Bowel Disease (IBD), in partnership with Takeda Pharmaceuticals.